TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to read, sign, and date the informed consent and HIPAA documents~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* Demonstrate a positive response when exposed to the Controlled Adverse Environment model~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any topical ophthalmic preparations (including artificial tear substitutes) 72 hrs prior to Visit 1 and during the study~* Any significant chronic illness that could interfere with study parameters~* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse~* Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5.0% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven colorectal cancer metastatic to the liver Unresectable disease Less than 50% invasion of the liver Measurable disease No prior irradiation Largest diameter at least 20 mm No detectable extrahepatic disease~PATIENT CHARACTERISTICS: Age: Under 75 Performance status: WHO 0-2 Life expectancy: Greater than 2 months Hematopoietic: WBC at least 4,000/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 35 micromoles/L Renal: Creatinine less than 130 micromoles/L Cardiovascular: No severe cardiac insufficiency Pulmonary: No respiratory disease that would preclude study Other: No other serious illness that would preclude study No psychological illness that would preclude study No peripheral neuropathy No prior malignancy not considered cured Not pregnant Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior intravenous oxaliplatin No more than 1 prior regimen of intravenous chemotherapy for metastatic disease Primary chemotherapy of fluorouracil allowed if stable or progressive disease No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with American Society of Anaesthesiologists physical status (ASA PS) I and II of age 18 to 65 years~* Patients undergoing laparoscopic totally extraperitoneal repair for unilateral/bilateral inguinal hernia.~Exclusion Criteria:~* Refusal to give consent.~* ASA physical status III or more.~* Inability to comprehend pain assessment score or severe mental impairment~* Patient who weighed \< 40 kg or \>100 kg~* Severe underlying cardiac rhythm disorder~* Renal or hepatic disease~* Allergic to local anaesthetics~* Epilepsy~* Patients on regular analgesics or anti-arrhythmic drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study in Participants With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed~* Have adequate organ function~* Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment~* Part A: Must have diagnosis of cancer that is advanced or metastatic~* Part B: Must have histologically confirmed squamous cell cancer of the head and neck or must have squamous cell cancer of any tumor type~* Part C: Must have histological diagnosis of squamous cell cancer of the head and neck, histological or cytological diagnosis of squamous non-small-cell lung cancer, or histological diagnosis of Stage IIIB (N2 or N3) or Stage IV squamous cell cancer of the anus that is not curable by local therapy~* Must be available during the duration of the study and willing to follow the study procedures~* If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug~* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding~Exclusion Criteria:~* Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment~* Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C~* Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months~* Must not have systolic blood pressure \<90 millimeters of mercury (mmHg) or recurrent symptomatic orthostatic hypotension~* Must not have a family history of long QTc syndrome or be taking drugs known to cause QTc prolongation or Torsades de Pointes~* Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome~* Must not have acute leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prexasertib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Online Intervention for ANHPI College Students

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be registered undergraduate student at University of Hawaii at Manoa, University of Hawaii at Hilo, or Hawaii Pacific University~* Must be over the age of 18yrs~Exclusion Criteria:~* Not an undergraduate college student at one of the participating university sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- First initiation site (Type: EXPERIMENTAL): University randomized to receive intervention after 1 baseline assessment. Duration of intervention was 3 semesters. This was University of Hawaii at Manoa (UHM).
- Second initiation site (Type: EXPERIMENTAL): University randomized to receive intervention after 3 baseline assessments. Duration of intervention was 2 semesters. This was University of Hawaii at Hilo (UHH).
- Third initiation site (Type: EXPERIMENTAL): University randomized to receive intervention after 5 baseline assessments. Duration of intervention was 2 semesters. This was Hawaii Pacific University (HPU).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TH9507 in Patients With HIV-Associated Lipodystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 65 years inclusive~* HIV positive; CD4 cell counts \>100 cells/mm3; viral load \<10,000 copies/mL (stable for 8 weeks)~* On stable ART regimen for at least 8 weeks prior to randomization~* Have evidence of abdominal fat accumulation defined by the following anthropometric cut off values:~  * For males: waist circumference \> 95 cm and waist to hip ratio \> 0.94;~ * For females: waist circumference \> 94 cm and waist to hip ratio \> 0.88.~* Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.~* Signed informed consent~Exclusion Criteria:~* Body mass index \< 20 kg/m2~* Opportunistic infection; HIV-related disease within 3 months of study.~* History of malignancy; active neoplasm.~* Prostate-specific antigen (PSA) \>5 ng/mL at screening~* Hypopituitarism; history of pituitary tumor/surgery; head irradiation; head trauma that has affected the somatotropic axis.~* Untreated hypothyroidism~* Type 1 diabetics and type 2 diabetics on oral hypoglycemic or insulin sensitizing agent within 6 months of study~* ALT or AST \> 3 x ULN; serum creatinine \> 133 mmol/L (1.5 mg/dL); hemoglobin more than 20 g/L below LLN; fasting blood glucose \> 8.33 mmol/L (150 mg/dL); fasting triglycerides \> 11.3 mmol/L (0.99 g/dL).~* Untreated hypertension~* Change in anti-hyperlipemic regimen within 3 months prior to study~* Change in testosterone regimen and/or supraphysiological dose of testosterone~* Estrogen therapy~* Anoretics/anorexigenics or anti-obesity agents within 3 months of study~* Growth hormone (GH); GH secretagogues; growth hormone releasing factor (GRF) products; IGF-1; or IGFBP-3 within 6 months of study.~* Drug or alcohol dependence or use of methadone within 6 months of study entry~* Participation in a clinical trial with any investigational drug/device within 30 days of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be male or female between the ages of 18 and 70~* Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnosis of bipolar disorder (type I, II, or NOS)~* Currently depressed as confirmed by the MINI-Plus at the screening visit~* Currently receiving treatment with an anti-manic drug~* Meets criteria for metabolic syndrome or insulin resistance~Exclusion Criteria:~* Pregnancy or breast feeding~* Unstable or inadequately treated medical illness as judged by the investigator~* Severe personality disorder~* Serious suicidal risk~* Known history of intolerance or hypersensitivity to pioglitazone~* Treatment with pioglitazone in the 3 months prior to randomization~* Dependence on alcohol or drugs (other than nicotine) in the 3 months prior to study entry~* Currently taking an antidiabetic/glucose-lowering agent.~* Diagnosed with dementia~* Acute Mania as defined by a Young Mania Rating Scale (YMRS) score \> 15~* Diagnosed with heart failure~* Transaminase elevation \>2.5 times the upper limit of normal~* Presence of renal impairment (eg. creatinine \> 1.5)~* Fasting blood glucose \>150 mg/dL~* Hb A1c \> 7.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Foxiga Korea Local Phase 4 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults with T2DM (Male or female, ≥ 19 and ≤ 75 yrs)~2. Patients in insufficient glycemic control (HbA1c \> 7.5% and \< 9.5% in recent 4 weeks)~3. Patients with an unchanged dose of metformin (≥ 1,000 mg/day) for \> 8 weeks prior to randomization~4. Written informed consent~5. WOCBP must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose.~   * WOCBP must have a negative urine pregnancy test at screening visit WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal.~  * WOCBP must be willing to use a medically accepted method of contraception that is considered reliable in the judgment of the Investigator.~Exclusion Criteria:~1. Type 1 diabetes or history of diabetic ketoacidosis~2. Pregnant or breast-feeding patients~3. eGFR \< 60 mL/min/1.73 m2 (MDRD) on visit 1.~4. Indication of active liver disease (AST/ALT/total bilirubin \> 3 X upper limits of normal) on visit 1.~5. Acute coronary syndrome, stroke or TIA within 3 months prior to randomization~6. Bariatric surgery within 2 years; treatment of anti-obesity drugs 3 months prior to randomization; any treatment leading to unstable body weight. (Unstable body weight is considered reliable in the judgment of the Investigator.)~7. History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time~8. History of any other malignancy within 5 years (with the exception of successfully treated non-melanoma skin cancers)~9. History of alcohol or drug abuse judged by physician within 3 months prior to randomization~10. Concomitant participation in any other clinical study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin 10mg + Metformin 1000mg
- Glimepiride (Type: ACTIVE_COMPARATOR): Glimepiriide 1-2mg + Metformin 1000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject was treated under Protocol CG-CIP01 or CG-CIP02 and completed 12 month follow-up period~* The subject has understood and signed a Research Ethics Board(REB) approved Informed Consent Form (ICF)~Exclusion Criteria:~* The subject was not treated under Protocol CG-CIP01-P or CG-CIP02-P~* The subject did not complete 12 month follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: None): Microfracture with BST-CarGel
- Control (Type: None): Microfracture without BST-CarGel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;~* The average VAS score of pain in the week before enrollment is ≥4;~* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);~* Women aged 18 to 55 (including 18 and 55) with a history of sexual life;~* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.~Exclusion Criteria:~* Pelvic inflammatory disease (acute attack);~* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 3 months after the trial;~* Critically ill or with surgical indications;~* Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;~* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, etc.;~* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;~* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;~* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;~* Have a history of allergy to the components of the test drug;~* Participated in other clinical trials within the past 3 months;~* The investigator believes that it is not suitable to participate in this clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Jincaopian Tablets high-dose group (Type: EXPERIMENTAL): Patients receive high dose Jincaopian Tablets 0.6g/day for 12 weeks.
- Jincaopian Tablets low-dose group (Type: EXPERIMENTAL): Patients receive low dose Jincaopian Tablets 0.3g/day for 12 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients receive a matching placebo for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-60 year-old~* American Society of Anesthesiology(ASA) status I\~II~* Elective craniotomy patients with supratentorial eloquent glioma diagnosed by MRI (In control group: volunteers without neuro-diseases)~Exclusion Criteria:~* Unable to comprehend and cooperate with the neurologic examination~* Impaired mental status~* Taking sedative drugs in the past 24 hours~* Taking pain reliever in the past 24 hours~* Drug and/or alcohol abuse~* Pregnant and/o lactating women~* Recurrent brain tumors~* Multiple brain tumors~* Accepting radiotherapy or chemotherapy~* Complicated with intracranial trauma and vascular diseases~* Complicated with grand mal epilepsy ( in midazolam group)~* Complicated with neuromuscular diseases~* Complicated with cutaneous paresthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Glioma group (Type: EXPERIMENTAL): Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
- non-neurosurgical group (Type: ACTIVE_COMPARATOR): patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete